NBD AI Bulletin - Dashenlin Pharmaceutical Group Co Ltd (the Company, SH 603233, close price: 97.14 yuan) announced on February 8 that the Company would provide joint liability guarantee for majority-owned subsidiaries Jiangxi Dashenlin Pharmaceutical Technology and Nantong Jianghai Pharmacy Chain Co., Ltd.'s comprehensive credit line of 75 million yuan from banks.

The 2020 semiannual report shows that the main business of Dashenlin Pharmaceutical Group Co Ltd is pharmaceutical retail, pharmaceutical wholesale, accounting for 94.95%, 3.02% of revenue, respectively.

Dashenlin Pharmaceutical Group Co Ltd's chairman is Ke Yunfeng, male, 54 years old, Chinese national, no permanent overseas residency, MBA, economist. Dashenlin Pharmaceutical Group Co Ltd's general manager is Ke Guoqiang, male, 39 years old, Chinese national, no permanent overseas residency, undergraduate degree, pharmacist, assistant human resources manager.

Tips on "Stock Trends":

1. The number of shares held by northbound investors in the Company increased by 3.0531 million in the past 30 days, representing 0.47% of the Company's circulating shares;

2. There was no institutional research on the Company in the past 30 days.  

(By Lan Suying)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.